Research Synopsis
Innovation for optimized detection and analysis of circulating tumor DNA (ctDNA). Analysis of ctDNA has the potential to revolutionize cancer detection and management. The Bratman Lab is a persistent source of innovation in ctDNA and other 'liquid biopsy' technologies. This includes methods for analysis of genetic, microbial, and epigenetic aberrations in circulating DNA. We develop novel molecular biology, sequencing, and bioinformatics approaches with the ultimate goal of clinical utility and adoption. We are also interested in the biology of circulating DNA and ctDNA release.

Personalized cancer medicine for head and neck cancer (HNC). As a radiation oncologist who treats patients with HNC, Dr. Bratman pursues a research agenda aimed at benefiting HNC patients. Many HNC patients endure poor outcomes despite treatment regimens such as chemo-radiotherapy that can cause significant toxicities. Thus, novel therapeutic strategies and innovative biomarkers are needed to improve management of this disease. The Bratman Lab is developing new radiation sensitizers with the goal of more tailored, tolerable, and effective treatment. The group is also pursuing molecular biomarkers to enable earlier diagnosis of cancer, risk stratification, and treatment individualization.